<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108833</url>
  </required_header>
  <id_info>
    <org_study_id>TASLY-B1448</org_study_id>
    <nct_id>NCT03108833</nct_id>
  </id_info>
  <brief_title>A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism</brief_title>
  <acronym>ERUPTE</acronym>
  <official_title>A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is being conducted to assess the efficacy and safety of recombinant Human&#xD;
      Prourokinase in the acute pulmonary embolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qanadli CT Score</measure>
    <time_frame>0 and 48hours after treatment</time_frame>
    <description>Change of Qanadli Score from baseline by CTPA 48hours after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average pulmonary artery pressure</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of average pulmonary artery pressure from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Three tricuspid regurgitation velocity</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of Three tricuspid regurgitation velocity from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RV to LV Diameter Ratio(Ultrasonic echocardiography)</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of RV to LV Diameter Ratio from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RV to LV Diameter Ratio(CTPA)</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of RV to LV Diameter Ratio from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary systolic pressure</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of pulmonary systolic pressure from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>0，48hours and 30days after treatment</time_frame>
    <description>Changes of NT-proBNP from baseline 48hours and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>From baseline to 30 days</time_frame>
    <description>The frequency of major bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bleeding</measure>
    <time_frame>From baseline to 30 days</time_frame>
    <description>The frequency of bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death from all causes</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>Incidence of death from all causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of recurrent pulmonary embolism</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>Incidence of recurrent pulmonary embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death from all causes</measure>
    <time_frame>From baseline to 30 days</time_frame>
    <description>Incidence of death from all causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hemodynamic deterioration</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>Incidence of hemodynamic deterioration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Low Dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Prourokinase:40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Prourokinase:50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator Controlled Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase:100mg if weight&gt;=65kg, 1.5mg/kg if weight&lt;65kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Prourokinase</intervention_name>
    <description>The drug is used for intravenous thrombolysis therapy</description>
    <arm_group_label>High Dose Experimental Group</arm_group_label>
    <arm_group_label>Low Dose Experimental Group</arm_group_label>
    <other_name>rhPro-UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>The drug is used for intravenous thrombolysis therapy</description>
    <arm_group_label>Active Comparator Controlled Group</arm_group_label>
    <other_name>Actilyse</other_name>
    <other_name>rtPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years（Include the critical value）AND&#xD;
&#xD;
          2. High-risk PE or medium high-risk PE AND&#xD;
&#xD;
          3. PE symptom duration ≤14 days AND&#xD;
&#xD;
          4. PLT≥100×10^9/L，ALT and AST≤2.5ULN，TBIL&lt;ULN，Cr within the normal range AND&#xD;
&#xD;
          5. Informed consent can be obtained from subject or Legally Authorized Representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemorrhagic or unexplained stroke history&#xD;
&#xD;
          2. Ischemic stroke or transient ischemic attack (TIA) within 6 months&#xD;
&#xD;
          3. The existence of the central nervous system injury or tumor&#xD;
&#xD;
          4. Severe trauma，major surgery or head injury within 3 weeks&#xD;
&#xD;
          5. Active bleeding within 1 month&#xD;
&#xD;
          6. Clinician deems high-risk for bleeding&#xD;
&#xD;
          7. Using anticoagulants (after a washout period can be randomized)&#xD;
&#xD;
          8. Pregnancy or delivery within 1 week&#xD;
&#xD;
          9. Vascular puncture which can not be oppressed&#xD;
&#xD;
         10. Cardiopulmonary resuscitation within 10 days&#xD;
&#xD;
         11. Systolic blood pressure above 180 mmHg or diastolic blood pressure above 100mmHg&#xD;
&#xD;
         12. Severe liver dysfunction&#xD;
&#xD;
         13. Infective endocarditis&#xD;
&#xD;
         14. Arterial aneurysm or arteriovenous malformation or suspected aortic dissection&#xD;
&#xD;
         15. left atrial thrombus&#xD;
&#xD;
         16. Neurosurgery or eye surgery within 1 month&#xD;
&#xD;
         17. Hemorrhagic diabetic retinopathy&#xD;
&#xD;
         18. Serious cardiac insufficiency&#xD;
&#xD;
         19. ventricular arrhythmias&#xD;
&#xD;
         20. Known allergic to prourokinase，urokinase，recombinant tissue-type plasminogen&#xD;
             activator，contrast agent or any drug in the trial&#xD;
&#xD;
         21. Do not allow for 30 days' study&#xD;
&#xD;
         22. Any disease or condition is not suitable for intravenous thrombolysis&#xD;
&#xD;
         23. Lactating women or plan to pregnant women during the trial，or don't want to during the&#xD;
             study period using effective contraception or abstinence of male and female patients&#xD;
             with possibility of fertility&#xD;
&#xD;
         24. Clinician thinks patient doesn't fit to participate in the test of other diseases or&#xD;
             conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Saruplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

